Personalized medicine--trends in molecular diagnostics: exponential growth expected in the next ten years.

@article{Hoggatt2011PersonalizedMI,
  title={Personalized medicine--trends in molecular diagnostics: exponential growth expected in the next ten years.},
  author={Julie Hoggatt},
  journal={Molecular diagnosis & therapy},
  year={2011},
  volume={15 1},
  pages={53-5}
}
Companion diagnostics and stratified medicines will be increasingly used over the next ten years. Current market leaders who have created diagnostic divisions with a focus on biomarker identification will benefit, notably Abbott, AstraZeneca, Novartis, and GlaxoSmithKline. Pricing incentives and improvement in efficacy will drive this market. The US FDA is not likely to mandate stratification of medications, but cost containment for clinical trials will be sufficient incentive for companies to… CONTINUE READING